Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Rom J Morphol Embryol ; 53(3): 461-6, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22990533

RESUMO

The way for explanation postischemic dementia processes has been one fraught with a wide range of complications and frequent revisions with a lack of a final clear solution. Data from animal models of brain ischemia and human ischemic brains studies have demonstrated an overexpression of amyloid precursor protein and increase production of a ß-amyloid peptide. Restoration brain activity following ischemic brain episode is delayed and not always complete due to an alteration related with increase in the level of the ß-amyloid peptide. In this paper, we will propose our idea about production of the ß-amyloid peptide from the amyloid precursor protein in ischemic brain lesions, and how this protein presents etiological and therapeutic targets that are now under consideration. Maturation of the ischemic brain tissue pathology may be caused not only by a neurodegeneration of selectively vulnerable neuronal cells destroyed following ischemia but also by acute and chronic pathology of resistant parts of the brain and chronic changes in the blood-brain barrier. We propose that in dementia following ischemia an initial ischemic episode precedes the brain tissue deposition of ß-amyloid peptide, which in turn amplifies the vascular dysfunction after first episode of ischemia triggering next focal ischemic episodes as vicious cycle preceding final ischemic degenerative changes and may gradually over a lifetime, progress to brain atrophy and finally to postischemic dementia with Alzheimer's phenotype.


Assuntos
Doença de Alzheimer/complicações , Precursor de Proteína beta-Amiloide/metabolismo , Isquemia Encefálica/patologia , Encéfalo/irrigação sanguínea , Encéfalo/patologia , Demência/etiologia , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Animais , Barreira Hematoencefálica/metabolismo , Barreira Hematoencefálica/patologia , Encéfalo/metabolismo , Isquemia Encefálica/metabolismo , Demência/metabolismo , Demência/patologia , Modelos Animais de Doenças , Humanos
2.
Physiol Res ; 60(Suppl 1): S113-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21777016

RESUMO

Ongoing interest in brain ischemia research has provided data showing that ischemia may be involved in the pathogenesis of Alzheimer disease. Brain ischemia in the rat produces a stereotyped pattern of selective neuronal degeneration, which mimics early Alzheimer disease pathology. The objective of this study was to further develop and characterize cardiac arrest model in rats, which provides practical way to analyze Alzheimer-type neurodegeneration. Rats were made ischemic by cardiac arrest. Blood-brain barrier (BBB) insufficiency, accumulation of different parts of amyloid precursor protein (APP) and platelets inside and outside BBB vessels were investigated in ischemic brain up to 1-year survival. Ischemic brain tissue demonstrated haphazard BBB changes. Toxic fragments of APP deposits were associated with the BBB vessels. Moreover our study revealed platelet aggregates in- and outside BBB vessels. Toxic parts of APP and platelet aggregates correlated very well with BBB permeability. Progressive injury of the ischemic brain parenchyma may be caused not only by a degeneration of neurons destroyed during ischemia but also by chronic damage in BBB. Chronic ischemic BBB insufficiency with accumulation of toxic components of APP in the brain tissue perivascular space, may gradually over a lifetime, progress to brain atrophy and to full blown Alzheimer-type pathology.


Assuntos
Doença de Alzheimer/etiologia , Precursor de Proteína beta-Amiloide/metabolismo , Isquemia Encefálica/complicações , Encéfalo/metabolismo , Degeneração Neural/etiologia , Doença de Alzheimer/metabolismo , Doença de Alzheimer/patologia , Animais , Atrofia , Barreira Hematoencefálica/metabolismo , Barreira Hematoencefálica/patologia , Encéfalo/patologia , Isquemia Encefálica/etiologia , Isquemia Encefálica/metabolismo , Isquemia Encefálica/patologia , Modelos Animais de Doenças , Progressão da Doença , Feminino , Parada Cardíaca/complicações , Degeneração Neural/metabolismo , Degeneração Neural/patologia , Permeabilidade , Agregação Plaquetária , Ratos , Ratos Wistar , Fatores de Tempo
3.
Acta Neurochir Suppl ; 96: 267-71, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16671468

RESUMO

Our study demonstrates that ischemia-reperfusion brain injury induces an increase in blood-brain barrier (BBB) permeability in the periventricular white matter. This chronic insufficiency of BBB may allow entry of neurotoxic fragments of amyloid precursor protein (APP) and other blood components such as platelets into the perineurovascular white matter tissue. These components may have secondary and chronic harmful effects on the ischemic myelin and axons and can intensify the phagocytic activity of microglial cells. Pathological accumulation of toxic fragments of APP in myelinated axons and oligodendrocytes appears after ischemic BBB injury and seem to be concomitant with, but independent of neuronal injury. It seems that ischemia-reperfusion disturbances may play important roles, both directly and indirectly, in the pathogenesis of white matter lesions. This pathology appears to have distribution similar to that of sporadic Alzheimer's disease. We noted micro-BBB openings in ischemic white matter lesions that probably would act as seeds of future Alzheimer's-type pathology.


Assuntos
Precursor de Proteína beta-Amiloide/metabolismo , Barreira Hematoencefálica/fisiopatologia , Fibras Nervosas Mielinizadas/metabolismo , Doenças Neurodegenerativas/metabolismo , Doenças Neurodegenerativas/patologia , Traumatismo por Reperfusão/metabolismo , Traumatismo por Reperfusão/patologia , Animais , Barreira Hematoencefálica/patologia , Encéfalo/irrigação sanguínea , Encéfalo/patologia , Encéfalo/fisiopatologia , Feminino , Fibras Nervosas Mielinizadas/patologia , Doenças Neurodegenerativas/etiologia , Ratos , Ratos Wistar , Traumatismo por Reperfusão/complicações , Fatores de Tempo , Distribuição Tecidual
4.
Brain Res ; 987(2): 186-93, 2003 Oct 17.
Artigo em Inglês | MEDLINE | ID: mdl-14499962

RESUMO

Transient global ischemia induces intensive neuronal degeneration in the hippocampal CA1 pyramidal layer, accompanied by reactive transformation of glial cells. Previously, we have shown using the double immunostaining method that the NGF receptors (NGFR) p75 and TrkA are expressed mainly on subpopulations of GFAP+ astrocytes, and this expression increases progressively after ischemia. In the presented study, we analyzed quantitatively the morphological transformations of cells immunopositive for GFAP or NGF receptors in the stratum radiatum of the CA1 hippocampal area in different survival periods after ischemia, evoked by 10-min cardiac arrest in adult rats. In control brains, NGF receptors were expressed only on small cells with poorly ramified processes. After ischemia, the NGFR+ cells increased in size and morphological complexity (measured using fractal analysis). However, even 2 weeks after ischemia these cells did not reach the size and value of the fractal dimension typical of the largest GFAP+ astrocytes. Moreover, the reaction of NGFR+ cells was significantly delayed in comparison with the total astrocyte population. The obtained results suggest that NGF receptors are expressed mainly by immature astrocytes and ischemia induces the maturation of these cells.


Assuntos
Proteínas de Transporte/biossíntese , Proteína Glial Fibrilar Ácida/biossíntese , Hipocampo/metabolismo , Ataque Isquêmico Transitório/metabolismo , Proteínas de Membrana/biossíntese , Receptor de Fator de Crescimento Neural/biossíntese , Receptor trkA , Animais , Feminino , Hipocampo/citologia , Ataque Isquêmico Transitório/patologia , Ratos , Ratos Wistar
5.
Neuroscience ; 120(1): 31-40, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12849738

RESUMO

We have examined the effect of global transient cerebral ischemia, evoked in rat by 10 min of cardiac arrest, upon the changes in the cellular expression of two nerve growth factor (NGF) receptors (TrkA and p75) in the hippocampus. We have used immunocytochemical procedures, including a quantitative analysis of staining, along with some quantitative morphological analyses. We have found, under ischemic conditions, a decrease of TrkA immunoreactivity in degenerating CA1 pyramidal neurons and in neuropil. On the other hand, a strong, ischemia-induced up-regulation of TrkA and p75 immunoreactivity was observed in the majority of reactive astroglia population in the adjacent CA1 hippocampal region. The colocalization of the two receptors in the same reactive astroglial cells was evidenced by double immunostaining and further supported by quantitative morphological analysis of TrkA and p75 immunoreactive glial cells. Our data implicate the involvement of NGF receptors in the postischemic regulation of astrocytic function; however, the lack of NGF receptor expression on some astrocytes suggests heterogeneity of astroglia population. Our results also indicate that the lack of neuroprotective action of astroglial NGF induced in the ischemic hippocampus [J Neurosci Res 41 (1995) 684; Acta Neurobiol Exp 57 (1997) 31; Neuroscience 91 (1999) 1027] is not caused by a paucity of NGF receptors but may rather be due to the counteraction of some proinflammatory substances, released simultaneously by glia cells. On the other hand, the up-regulated astroglial TrkA receptor may be an important target for exogenous NGF, which, as previously described [J Neurosci 11 (1991) 2914; Neurosci Lett 141 (1992) 161], exerts a neuroprotective effect in ischemia.


Assuntos
Astrócitos/metabolismo , Ataque Isquêmico Transitório/metabolismo , Receptor de Fator de Crescimento Neural/biossíntese , Receptor trkA/biossíntese , Regulação para Cima/fisiologia , Animais , Astrócitos/patologia , Feminino , Ataque Isquêmico Transitório/patologia , Ratos , Ratos Wistar
6.
Neurochem Res ; 25(11): 1497-502, 2000 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11071369

RESUMO

Subclinical hepatic encephalopathy (SHE) was produced in rats by two intraperitoneal injections of TAA at 24 h intervals and the animals were examined 21 days later. Concentrations of the neuroactive amino acids taurine (Tau), glutamate (Glu) and aspartate (Asp), were measured in the cerebral cortical microdialysates of thioacetamide (TAA)-treated and untreated control rats. During microdialysis some animals were awake while others were anesthetized with ketamine plus xylazine. There was no difference in the water content of cerebral cortical slices isolated from control and SHE rats, indicating a recovery from cerebral cortical edema that accompanies the acute, clinical phase of hepatic encephalopathy in this model. When microdialysis was carried out in awake rats, dialysate concentrations of all the three amino acids were 30% to 50% higher in SHE rats than in control rats. Ketamine anesthesia caused a 2.2% increase of water content of cerebral cortical slices and increased Asp, Glu, and Tau concentration in microdialysates of control rats. In SHE rats, ketamine anesthesia produced a similar degree of cerebral edema, however, it did not alter Asp and Glu concentrations in the microdialysates. These data may reflect on one hand a neuropathological process of excitotoxic neuronal damage related to increased Glu and Asp, on the other hand neuroprotection from neuronal swelling indicated by Tau redistribution in the cerebral cortex. The reduction of the effects of SHE on Glu and Asp content in ketamine-anesthesized rats is likely to be due to interference of ketamine with the NMDA receptor-mediated component of the SHE-evoked excitatory neurotransmitter efflux and/or reuptake of the two amino acids. By contrast, the SHE-related increase of Tau content was not affected by ketamine anesthesia, indicating that the mechanism(s) underlying SHE-evoked accumulation of Tau must be different from the mechanism causing release of excitatory amino acids. The results with ketamine advocate caution when using this anesthetic in studies employing the cerebral microdialysis technique for measurement of extracellular amino acids.


Assuntos
Anestésicos Dissociativos/farmacologia , Ácido Aspártico/metabolismo , Córtex Cerebral/metabolismo , Ácido Glutâmico/metabolismo , Ketamina/farmacologia , Falência Hepática/induzido quimicamente , Taurina/metabolismo , Tioacetamida/toxicidade , Animais , Água Corporal , Espaço Extracelular/metabolismo , Masculino , Microdiálise , Ratos , Ratos Wistar
7.
Resuscitation ; 47(2): 195-201, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11008159

RESUMO

This study was designed to determine the effects of global cerebral ischaemia caused by temporary cardiac arrest and the early and late consequences of this ischaemia on dopamine transport and dopamine D(2) receptor binding in rat brain. The effects of 10 min of global ischaemia were measured immediately and after 1 h and 7 days post-resuscitation. A decrease of dopamine uptake in the rats by synaptosomes was noted immediately following global ischaemia and 1 h after resuscitation. However, at 7 days post-resuscitation, the dopamine uptake returned to control values. Reversibility of the changes in the synaptosomal dopamine uptake is undoubtedly a favourable sign. Global ischaemia and reperfusion after 1 h or 7 days did not show altered rates of dopamine release but did affect the dopamine D(2) receptor. An observed increase of receptor affinity may be an adaptive response to the reduction in binding capacity. The reduction of visible D(2) receptor binding sites in the early post-resuscitation phase, which was extended to the period of 7 days after resuscitation without recovery, is probably associated with neuronal necrotic damage.


Assuntos
Isquemia Encefálica/etiologia , Dopamina/metabolismo , Parada Cardíaca/complicações , Receptores de Dopamina D2/metabolismo , Animais , Transporte Biológico Ativo , Isquemia Encefálica/metabolismo , Parada Cardíaca/metabolismo , Masculino , Ratos , Ratos Wistar
8.
Acta Neurochir Suppl ; 76: 73-7, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11450095

RESUMO

Our experiments were performed to test the hypothesis that human beta-amyloid peptide 42 (beta A) is able to enter and exit the brain parenchyma through the blood-brain barrier. In an effort to determine the effect of beta A in an animal model, we have injected beta A i.v. into rats following single and repeated brain ischemia. Rats were sacrificed at 3 and 12 months after injection and beta A was localized by monoclonal antibody (mAb) 4G8. The present observations revealed an abundant presence of beta A in the extracellular space of the brain, which appeared to be dilated, and a vigorous uptake of beta A into the cytoplasm of endothelial and ependymal cells, pericytes, astrocytes and neurons. Some of the beta A deposits were associated and/or had migrated to the vessels and to the ventricles, and by 3 months a significant amount of beta A was directly associated with the vessels and was observed inside the ventricular space. Virtually no soluble and aggregating beta A was found in brain tissue 1 year later. This suggests that phagocytic pericytes and astrocytes take up exogenous beta A in an attempt to clear the peptide from the brain extracellular space and deliver it to the circulation. Further, direct removal of beta A from the ventricles by the bloodstream is also possible. These observations suggest that a reverse transport of beta A across endothelial cells of microvessels represents one of the possible mechanisms responsible for removal of extravasated beta A. The findings of the present study indicate that in normal conditions beta A is rapidly cleared from the cerebrospinal fluid and brain parenchyma, suggesting that irreversible changes in the physico-chemical properties of the cerebrovascular endothelial cell surface are involved in beta A deposition in the brain in Alzheimer's disease (AD).


Assuntos
Peptídeos beta-Amiloides/sangue , Barreira Hematoencefálica/fisiologia , Ataque Isquêmico Transitório/patologia , Fragmentos de Peptídeos/sangue , Doença de Alzheimer/patologia , Animais , Encéfalo/patologia , Ventrículos Cerebrais/patologia , Endotélio Vascular/patologia , Feminino , Ratos , Ratos Wistar
9.
Neurosci Lett ; 263(1): 72-6, 1999 Mar 19.
Artigo em Inglês | MEDLINE | ID: mdl-10218914

RESUMO

We have investigated the pattern of expression of IL-1beta and IL-6 immunoreactivities in rat hippocampus after transient complete brain ischemia evoked by a 10 min cardiac arrest, at survival times ranging from 1 day to 28 days. To identify the cell types expressing the two immunoreactivities we used specific cell markers and combined staining procedures. In the intact brain IL-1beta and IL-6 were mainly localized in neurons particularly in pyramidal and granular cell layers. Ischemic insult resulted in a concomitant induction of IL-1beta and IL-6 immunoreactivities in multiple astroglia especially in the CA1 area which is the most vulnerable to ischemic insult as manifested by a massive delayed neuronal death accompanied by an intense gliosis. The number of astroglia expressing both immunoreactivities and the intensity of staining was maximal at the 14th day and remained at the same level at the 28th day. Our data suggest that the astroglial IL-1beta and IL-6 may affect the neurodegeneration of CA1 neurons in the ischemic hippocampus and that the prolonged proinflammatory effects of IL-1beta prevail over the presumed protective action of IL-6.


Assuntos
Astrócitos/imunologia , Hipocampo/imunologia , Interleucina-1/biossíntese , Interleucina-6/biossíntese , Ataque Isquêmico Transitório/imunologia , Animais , Parada Cardíaca , Hipocampo/metabolismo , Hipocampo/patologia , Inflamação , Interleucina-1/análise , Interleucina-6/análise , Ataque Isquêmico Transitório/metabolismo , Ataque Isquêmico Transitório/patologia , Masculino , Degeneração Neural , Neurônios/patologia , Células Piramidais/patologia , Ratos , Ratos Wistar , Fatores de Tempo
10.
Neuroreport ; 10(17): 3615-9, 1999 Nov 26.
Artigo em Inglês | MEDLINE | ID: mdl-10619654

RESUMO

Brains from patients with Alzheimer's disease contain diffuse and senile amyloid plaques. Using an experimental model, we have addressed the issue whether diffuse plaques of amyloid persist, develop with time, or both, in rats injected with human beta-amyloid-(1-42)-peptide for 3 and 12 mon after brain ischemia. Rats receiving beta-amyloid peptide for 3 months after brain ischemia demonstrated widespread diffuse amyloid plaques in hippocampus and cerebral cortex. Neuronal, glial, ependymal, endothelial and pericyte cell bodies were observed filled with beta-amyloid peptide. No staining was observed in control brains. In the group alive 1 year no deposition of human beta-amyloid peptide was observed, too. Direct evidence that diffuse amyloid plaques can disappear in the brain is thus provided for the first time.


Assuntos
Doença de Alzheimer/metabolismo , Peptídeos beta-Amiloides/fisiologia , Isquemia Encefálica/metabolismo , Encéfalo/metabolismo , Modelos Animais de Doenças , Placa Amiloide/metabolismo , Doença de Alzheimer/etiologia , Doença de Alzheimer/patologia , Peptídeos beta-Amiloides/administração & dosagem , Peptídeos beta-Amiloides/líquido cefalorraquidiano , Animais , Barreira Hematoencefálica/fisiologia , Encéfalo/irrigação sanguínea , Encéfalo/patologia , Isquemia Encefálica/patologia , Morte Celular , Córtex Cerebral/irrigação sanguínea , Córtex Cerebral/metabolismo , Córtex Cerebral/patologia , Feminino , Parada Cardíaca Induzida , Hipocampo/irrigação sanguínea , Hipocampo/metabolismo , Hipocampo/patologia , Humanos , Placa Amiloide/patologia , Ratos , Ratos Wistar , Fatores de Tempo
11.
Resuscitation ; 39(1-2): 107-13, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9918457

RESUMO

The study was designed to determine the effect of idebenone, an electron-trapping agent and free radical scavenger capable of crossing the blood-brain barrier, on cardiac arrest-induced oxidative brain stress. Stress indices used were the brain contents of thiobarbituric acid-reactive material (TBAR), conjugated dienes and protein and non-protein thiols. Twenty-four hours after receiving one oral dose of placebo or 100 mg kg(-1) idebenone, the rats were anaesthetized with diethyl ether and either decapitated immediately, or subjected to 7.5 min cardiac arrest induced by compression of the heart vessel bundle. The next groups of rats were sacrificed at the end of the cardiac arrest session, or resuscitated by external chest compression and artificial ventilation with air and sacrificed 15 min, 60 min, 24 h, and 72 h later while re-anesthetized with diethyl ether. Subsequent placebo or idebenone (100 mg kg(-1)) doses were given to the appropriate surviving rats once daily, beginning 8-10 min after the end of cardiac arrest session. Compared to pre-arrest values, TBAR and conjugated dienes' contents increased, respectively, by 339 and 286%, and protein and non-protein thiol contents decreased, respectively, by 69 and 85% within 60 min after the resuscitation in placebo-treated rats. Normalization of all oxidative stress indices in these rats was slow and incomplete even at 72 h. Idebenone treated rats showed no increase in TBAR contents, and a marked attenuation of changes in the other indices. These results show that oral idebenone greatly reduces oxidative brain stress following transient circulatory arrest in the rat. This effect could not be explained by simple stoichiometric scavenging of free radicals. Possible mechanisms of idebenone action are discussed.


Assuntos
Antioxidantes/uso terapêutico , Benzoquinonas/uso terapêutico , Encéfalo/metabolismo , Sequestradores de Radicais Livres/uso terapêutico , Parada Cardíaca/complicações , Estresse Oxidativo/fisiologia , Traumatismo por Reperfusão/tratamento farmacológico , Administração Oral , Animais , Antioxidantes/administração & dosagem , Barbitúricos/farmacologia , Benzoquinonas/administração & dosagem , Feminino , Sequestradores de Radicais Livres/administração & dosagem , Masculino , Ratos , Ratos Wistar , Traumatismo por Reperfusão/metabolismo , Compostos de Sulfidrila/metabolismo , Ubiquinona/análogos & derivados
12.
Neurosci Lett ; 232(2): 95-8, 1997 Aug 29.
Artigo em Inglês | MEDLINE | ID: mdl-9302095

RESUMO

We observed in extra- and intracellular space accumulation of different fragments of amyloid precursor protein (APP) and apolipoprotein E (Apo E) in rat brain after cardiac arrest with long-term survival. Idebenone treatment did not affect APP and Apo E alterations in this condition.


Assuntos
Precursor de Proteína beta-Amiloide/metabolismo , Apolipoproteínas E/metabolismo , Benzoquinonas/farmacologia , Isquemia Encefálica/metabolismo , Hipocampo/metabolismo , Peptídeos beta-Amiloides/metabolismo , Animais , Córtex Cerebral/irrigação sanguínea , Córtex Cerebral/metabolismo , Feminino , Hipocampo/irrigação sanguínea , Ratos , Ratos Wistar , Ubiquinona/análogos & derivados
13.
Acta Neurochir Suppl ; 70: 247-9, 1997.
Artigo em Inglês | MEDLINE | ID: mdl-9416336

RESUMO

In an attempt to produce an animal model of the Alzheimer's disease (AD), beta-amyloid-(1-42)-peptide (beta A1-42) was injected into the femoral vein in rats after single and repeated cardiac arrest (CA). After survival of 3.5 months, the brains immunoreactivity was evaluated using light microscopic immunocytochemistry of monoclonal beta-amyloid peptide (beta A) antibody 4G8 (mAb 4G8). Rats receiving beta A1-42 after CA demonstrated multifocal and widespread extravasation of beta A1-42 in extra- and intracellular space. The permeability to beta A1-42 was significantly higher in rats after repeated cerebral ischemia. As in AD, there were irregular diffuse amyloid plaque-like deposits and neuronal loss with reactive gliosis. Our data in ischemic rats with beta A1-42 represent a novel animal model of Alzheimer's pathology.


Assuntos
Peptídeos beta-Amiloides/farmacocinética , Barreira Hematoencefálica/fisiologia , Isquemia Encefálica/metabolismo , Fragmentos de Peptídeos/farmacocinética , Animais , Modelos Animais de Doenças , Extravasamento de Materiais Terapêuticos e Diagnósticos , Humanos , Ratos , Ratos Wistar
14.
Metab Brain Dis ; 11(3): 229-37, 1996 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8869943

RESUMO

The dibasic amino acids arginine (ARG), ornithine (ORN) and lysine (LYS) are transported by a common saturable transporter (system gamma +) at the blood-brain barrier (BBB). In the present study we compared the brain uptake index (BUI) for radiolabelled ORN, ARG and LYS in control rats and in rats treated with thioacetamide (TAA) to induce hepatic encephalopathy (HE). Some animals received i.v. ornithine aspartate (OA), a drug structurally related to the gamma + substrates that ameliorates neurological symptoms following liver damage by improving detoxification of ammonia in peripheral tissues: the compound was administered either by continuous infusion for 6h at a concentration of 2 g/kg (final blood concentration ranging from 0.19-0.5 mM), or as a 15 sec. bolus together with the radiolabelled amino acids, at a concentration of 0.35 mM. TAA treatment resulted in a delayed and progressive increase of BUI for ORN, to 186% of control at 7d post-treatment and to 345% of control at 21d post-treatment, when despite sustained liver damage, HE symptoms were already absent. In contrast, the BUI for ARG decreased to 30% of control at 7d post-treatment and remained low (42% of control) at 21d post-treatment. A 6h infusion of OA to untreated rats resulted in a reduction of the BUI for ARG and ORN to 51% and 62% of the control levels, respectively. Reductions of a similar magnitude were noted with both amino acids following the 15 sec OA bolus, indicating direct interaction of OA with the transport site in both cases. OA administered by either route abolished the enhancement of BUI for ORN, but did not further inhibit the BUI for ARG in the TAA-treated animals. The results indicate that some as yet unspecified factors released from damaged liver either modify the structure or conformation of the gamma + transporter at the BBB from the normally ARG-preferring to the ORN-preferring state, or activate (induce) a different transporter specific for ORN which is normally latent.


Assuntos
Arginina/metabolismo , Encéfalo/metabolismo , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Dipeptídeos/farmacologia , Lisina/metabolismo , Ornitina/metabolismo , Tioacetamida/toxicidade , Animais , Barreira Hematoencefálica , Encéfalo/efeitos dos fármacos , Doença Hepática Induzida por Substâncias e Drogas/complicações , Encefalopatia Hepática/induzido quimicamente , Encefalopatia Hepática/metabolismo , Infusões Intravenosas , Masculino , Ratos , Ratos Wistar
15.
Neuroreport ; 7(7): 1261-5, 1996 May 17.
Artigo em Inglês | MEDLINE | ID: mdl-8817545

RESUMO

Brains from patients with Alzheimer's disease contain amyloid plaques which are composed of beta-amyloid peptide and are considered to play a causal role in the neuropathology of this disease. The origin of beta-amyloid peptide in brain parenchyma and vessels of Alzheimer's disease patients is not known. This study examined the permeability of the blood-brain barrier to beta-amyloid peptide in rats subjected to single or repeated episodes of global cerebral ischaemia followed by i.v. injections of human synthetic beta-amyloid-(1-42)-peptide. Rats receiving beta-amyloid peptide after ischaemia demonstrated multifocal and widespread accumulation of beta-amyloid peptide in hippocampus, cerebral cortex and occasionally in white matter. beta-Amyloid peptide penetration involved arterioles, veins and venules. Neuronal, glial and pericyte bodies were observed filled with beta-amyloid peptide. Direct evidence that soluble human beta-amyloid-(1-42)-peptide crosses the blood-brain barrier and enters the brain from the circulation is thus provided for the first time.


Assuntos
Peptídeos beta-Amiloides/sangue , Barreira Hematoencefálica/fisiologia , Encéfalo/metabolismo , Proteínas do Tecido Nervoso/sangue , Animais , Isquemia Encefálica/metabolismo , Humanos , Ratos , Ratos Wistar
18.
Neuroreport ; 5(6): 671-3, 1994 Feb 24.
Artigo em Inglês | MEDLINE | ID: mdl-8199335

RESUMO

We measured the brain uptake index (BUI) for radiolabelled L-ornithine (ORN) in rats with acute hepatic encephalopathy (HE) induced by two (onset stage) or three (comatous stage) administrations of a hepatotoxin-thioacetamide (TAA). In the comatose group, an increase of the BUI to 275% of control was measured at 24 h post-treatment. In the onset group, the BUI for ORN increased gradually with time: it reached 220% of control at 7 days post-treatment and 442% of control at 21 days post-treatment. HE did not raise the BUI for a blood-brain barrier (BBB) non-penetrable amino acid L-aspartate (ASP), indicating that HE activates ORN transport but does not produce BBB leakage. ORN transport through BBB was not increased in rats with hyperammonemia comparable to that accompanying HE, but was induced without liver damage. Considering recent evidence that ORN acting intracerebrally ameliorates pathophysiological symptoms of HE, increased transport ORN across BBB should facilitate HE therapy based on systemic administration of this amino acid.


Assuntos
Encéfalo/metabolismo , Encefalopatia Hepática/metabolismo , Ornitina/metabolismo , Acetatos , Animais , Ácido Aspártico/metabolismo , Barreira Hematoencefálica/fisiologia , Endotélio/metabolismo , Encefalopatia Hepática/induzido quimicamente , Masculino , Modelos Biológicos , Ratos , Ratos Wistar , Tioacetamida/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...